Please ensure Javascript is enabled for purposes of website accessibility

How Big Is the COVID Vaccine Market for Younger Kids?

By Keith Speights - Updated Jun 24, 2021 at 8:13AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

This potential market is definitely large enough to motivate drugmakers to go after it.

Pfizer's (PFE -2.78%) COVID-19 vaccine can now be given to kids between the ages of 12 and 15. However, the big drugmaker is currently conducting clinical studies with the hopes of expanding the use of its vaccine to younger children. In this Motley Fool Live video recorded on May 17, healthcare and cannabis bureau chief Corinne Cardina and Motley Fool contributor Keith Speights discuss how big this potential market for younger kids could be.

Corinne Cardina: Let's do a similar back-of-the-envelope calculation for this younger age group for the market and contracts. What do you think about that?

Keith Speights: Yeah, this is, of course, it's a broader age range so you would expect the market would be bigger and you'd be right, the market is substantially bigger. The younger age group represents a really big market opportunity for these companies.

There are around 48 million kids in the U.S. who are ages 11 and below. And so even if we assume just one dose, let's just say one dose is all that would be required because they are looking at lower dosing with the kids. So let's say that works out, and instead of the two-dose regimen that adults get, it'll just be one dose for children. Let's say one dose is needed to immunize these younger kids.

This is a market that's close, not quite, but close to one billion dollars on an annualized basis. Again, that figure would assume 100% vaccination rate.

That probably isn't going to happen. It remains to be seen what the actual vaccination rates might be in younger children, and this also won't be a winner-take-all market. You're going to see all of the major players target the younger markets.

But I think both Pfizer and Moderna (MRNA 0.91%) will do very well in the younger age bracket, and they're going to make a lot of money. It's not going to be a billion dollars, I don't think, but I think you're going to see both of these companies end up making in the hundreds of millions of dollars from targeting vaccines for this younger age group.

Corinne Cardina owns shares of Moderna Inc. Keith Speights owns shares of Pfizer. The Motley Fool recommends Moderna Inc. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Pfizer Inc. Stock Quote
Pfizer Inc.
PFE
$48.56 (-2.78%) $-1.39
Moderna, Inc. Stock Quote
Moderna, Inc.
MRNA
$175.86 (0.91%) $1.59

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
390%
 
S&P 500 Returns
125%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/11/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.